Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer

BACKGROUND: Osimertinib is an irreversible tyrosine kinase inhibitor approved for the treatment of metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). In clinical trials, osimertinib has exhibited excellent activity and less toxicity compared to gefitinib,...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Marino, Pietro, Chiapperino, Cosima, Primavera, Francesca Chiara, Martino, Maria Teresa, Brocco, Davide, Carella, Consiglia, Grassadonia, Antonino, Tinari, Nicola, De Tursi, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012497/
https://www.ncbi.nlm.nih.gov/pubmed/35431558
http://dx.doi.org/10.2147/OTT.S315385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012497/
https://www.ncbi.nlm.nih.gov/pubmed/35431558
http://dx.doi.org/10.2147/OTT.S315385

Ejemplares similares